OmniAb (OABI) Change in Account Payables (2021 - 2022)

OmniAb's (OABI) quarterly Change in Account Payables came in at $1.8 million in Q3 2022, down 60.67% on a QoQ basis from $4.5 million in Q2 2022.

OmniAb (OABI) Change in Account Payables (2021 - 2022) Analysis & Trends

OmniAb (OABI) has 2 years of Change in Account Payables data on file, last reported at $1.8 million in Q3 2022.

On a quarterly basis, Change in Account Payables changed N/A year-over-year to $1.8 million in Q3 2022; TTM through Sep 2022 was $6.3 million, a N/A change from a year earlier, with the FY2021 full-year figure at $884.0, changed N/A from the prior year.
Change in Account Payables for Q3 2022 stood at $1.8 million, down from $4.5 million in the prior quarter.
Over the last five years, Change in Account Payables for OABI reached as high as $4.5 million in Q2 2022 and fell as low as -$32408.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Account Payables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-42.19 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-1.52 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	35.60 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	16.86 Mn
10	OmniAb	261.62 Mn	212.55 Mn	14.41 Mn	-

Download Data